PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-7.18%
Negative revenue growth while MRVL stands at 7.20%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-3.63%
Negative gross profit growth while MRVL is at 6.77%. Joel Greenblatt would examine cost competitiveness or demand decline.
-11.36%
Negative EBIT growth while MRVL is at 14.12%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-11.36%
Negative operating income growth while MRVL is at 14.12%. Joel Greenblatt would press for urgent turnaround measures.
-10.69%
Negative net income growth while MRVL stands at 15.63%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-9.76%
Negative EPS growth while MRVL is at 20.00%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-10.00%
Negative diluted EPS growth while MRVL is at 8.81%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-1.18%
Share reduction while MRVL is at 3.38%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-1.22%
Reduced diluted shares while MRVL is at 3.92%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
1.20%
Dividend growth of 1.20% while MRVL is flat. Bruce Berkowitz would see if this can become a bigger advantage long term.
-38.66%
Negative OCF growth while MRVL is at 1.58%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-73.49%
Negative FCF growth while MRVL is at 10.23%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
19.20%
10Y revenue/share CAGR under 50% of MRVL's 310.13%. Michael Burry would suspect a lasting competitive disadvantage.
47.21%
5Y revenue/share CAGR under 50% of MRVL's 310.13%. Michael Burry would suspect a significant competitive gap or product weakness.
60.39%
3Y revenue/share CAGR under 50% of MRVL's 212.77%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
839.85%
10Y OCF/share CAGR 1.25-1.5x MRVL's 563.63%. Bruce Berkowitz would confirm if the firm's long-term capital allocation yields better cash returns.
422.47%
5Y OCF/share CAGR at 50-75% of MRVL's 563.63%. Martin Whitman would question if the firm lags in monetizing revenue effectively.
199.68%
3Y OCF/share CAGR under 50% of MRVL's 494.36%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
243.23%
Below 50% of MRVL's 924.66%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
183.91%
Below 50% of MRVL's 924.66%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
427.26%
3Y net income/share CAGR above 1.5x MRVL's 273.99%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
154.02%
Below 50% of MRVL's 6240.53%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
-3.52%
Negative 5Y equity/share growth while MRVL is at 6240.53%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
10.46%
3Y equity/share CAGR similar to MRVL's 11.03%. Walter Schloss sees both having parallel profitability or reinvestment over 3 years.
43.45%
Dividend/share CAGR of 43.45% while MRVL is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
44.81%
Dividend/share CAGR of 44.81% while MRVL is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
36.80%
3Y dividend/share CAGR of 36.80% while MRVL is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
9.10%
AR growth well above MRVL's 2.08%. Michael Burry fears inflated revenue or higher default risk in the near future.
-2.12%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
-6.80%
Negative asset growth while MRVL invests at 3.72%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-4.73%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-51.89%
We’re deleveraging while MRVL stands at 23.52%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
6.60%
R&D growth drastically higher vs. MRVL's 3.34%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
-0.94%
We cut SG&A while MRVL invests at 2.71%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.